Abstract

ABSTRACT Aim: The purpose of the study was to analyze morphometry parameters in assessment of efficiency of different types of chemotherapy of uterine choriocarcinoma. Methods: Morphometric analysis was performed in 50 patients for determining quantitative characteristics of tumor before and after different types of chemotherapy. Results: Mitotic activity was rather high in untreated tumors (48,1‰). Most of mitoses were pathologic: chromosome lagging at metaphase - 13,6‰, c-mitoses - 7,9‰. Chromosome lagging at metaphase was observed in 28,3% of the cases, c-mitoses – in 16,4%. Intravenous chemotherapy significantly (by 4 times) reduced quantity of mitoses up to 12‰. Percent of c-mitoses increased up to 48,1%, that of orthomitoses decreased up to 20%. After combined (endolymphatic + intravenous) chemotherapy no viable cells were observed in the tumors. The level of dystrophic changes was rather high in untreated tumors (100,7‰). Karyolysis, vacuolization of the cytoplasm and nucleus vacuolization were the most frequent. Quantity of dystrophically changed cells increased up to 595,8‰ after intravenous chemotherapy. Karyopyknosis (248,2‰) and karyorhexis (145,1‰) were the most frequent. Separate cells or small cell complexes with pronounced signs of dystrophic changes (karyopyknosis and karyorhexis) were observed in sclerotic masses after the combined therapy. Tumor parenchyma and fibrinogenous hemorrhagic masses occupied similar total area in untreated tumors - 44,7 and 45,5% respectively. Necroses in parenchyma were microscopic (9,8%). Area of viable parenchyma reduced by almost 3 times after intravenous chemotherapy. Masses of packed fibrin occupied the same total area in tumor (45,8%) as fibrinogenous hemorrhagic masses did in untreated tumor (45,5%). Parenchyma remained in trace amounts after the combined therapy - 0,9%, necroses – 3,2%; fields of sclerosis with signs of hyalinosis occupied the main part of tumor – 95,6%. Conclusions: Morphometric parameters may be used in assessment of efficiency of different types of chemotherapy. Disclosure: All authors have declared no conflicts of interest.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call